
    
      Phase 2/3 trial in ALS patients Double-blinded, parallel, randomized (2 blocs, bulbar/spinal
      onset)

      Memantine + riluzole x Placebo + Memantine

      Inclusion criteria:

        -  < 75 years at disease onset

        -  < 3 years of disease progression

        -  ALS-FRS > 24

        -  FVC > 60

        -  Probable or definite disease (revised El Escorial criteria)

        -  No other medical condition

        -  Normal blood tests

        -  Regular medication on riluzole > 1 month

        -  Nerve conduction studies ruling out conduction block

        -  EMG with widespread loss of motor units (revised El Escorial criteria)

        -  At least one hand with ADM strength > 2 on MRC scale

      Duration - 2 years

      Evaluation - every 3 months

      Primary outcome - ALS-FRS Secondary -SF36, Hamilton depression scale, motor unit number
      estimation, neurophysiological index, strength (clinical evaluation); side-effects

      Intention to treat analysis

      60 patients

      number estimated for 50% change in decline rate of ALS-FRS
    
  